** Shares of genomic medicine company Sangamo Therapeutics SGMO.O rise 12.24% to $2.20 premarket
** Co says U.S. Food and Drug Administration has cleared co's application to start human trial for ST-503
** SGMO plans to initiate enrollment of patients in the early-to-mid stage study for ST-503 in mid-2025
** The therapy ST-503 is being studied for the treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN), a type of chronic nerve pain
** Up to last close, stock had more than tripled YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。